Bone and Mineral Metabolism Disorders News

Parathyroidectomies in secondary hyperparathyroidism result in significantly higher costs and higher rates of morbidity, mortality and complications compared to primary hyperparathyroidism, according to a speaker at the virtual National Kidney Foundation Spring Clinical Meetings.

Data from Fresenius Medical Care North America-directed ESRD Seamless Care Organizations show the type of phosphate binder used by clinics during the demonstration influenced hospital admissions and overall cost of care, according to an abstract at the virtual National Kidney Foundation Spring Clinical Meetings.

For patients with chronic kidney disease and diabetes, veverimer appeared to be an effective treatment for metabolic acidosis, as it improved both quality of life and physical function, according to phase 3 trial results. The results were presented virtually at the National Kidney Foundation Spring Clinical Meetings.

Phase 3 results from the PHREEDOM study demonstrated treatment with tenapanor safely and effectively decreased serum phosphorous in patients with chronic kidney disease on dialysis, according to a press release from Ardelyx Inc.

WASHINGTON — Use of the sucroferric oxyhydroxide binder by Fresenius Medical Care Renal Therapies Group, Velphoro, was effective in lowering serum phosphorus levels for patients in their first year of hemodialysis therapy, according to results presented here.

WASHINGTON — Patiromer was effective in controlling serum potassium in hyperkalemic patients with diabetes and advanced kidney disease on renin-angiotensin-aldosterone system inhibitors, according to research presented here.

WASHINGTON — For patients on hemodialysis who eat rice as a main source of calories, low-protein rice plus low-phosphorus whey can reduce serum phosphorus and improve serum albumin, according to study results presented at ASN Kidney Week.

Researchers of a published study found patients on hemodialysis who had secondary hyperparathyroidism were able to detect a worsening of symptoms related to increases in parathyroid hormone levels.

PHILADELPHIA — Concomitant use of the potassium binder patiromer enabled more patients with resistant hypertension and advanced chronic kidney disease to continue treatment with spironolactone, with less hyperkalemia, according to new data from the AMBER trial presented at the Heart Failure Society of America Scientific Meeting.

Researchers found differences for levels of parathyroid hormone, calcium and phosphorus in the first 5 years of hemodialysis based on patient race and country of origin.